期刊文献+

生物制剂在特应性皮炎治疗中的应用 被引量:2

Biologics in the Treatment of Atopic Dermatitis
下载PDF
导出
摘要 特应性皮炎是一种慢性、易反复、伴瘙痒的炎症性皮肤疾病,其发病率高且难以根治,给患者、社会及医疗系统带来较大负担。特应性皮炎发病机制错综复杂,2型炎症、17型炎症、角质形成细胞反应等免疫异常、表皮屏障功能破坏和菌群失调均被认为与特应性皮炎的发病紧密相关。目前,多种靶向特应性皮炎发病关键靶点的生物制剂已被研发,部分已成功应用于临床,并展现出较好的治疗有效性和安全性,给特应性皮炎的治疗提供了新方向。 Atopic dermatitis is a chronic,recurrent and pruritic inflammatory skin disease that is highly prevalent and difficult to treat,bring a large burden on patients,society,and the healthcare system.The pathogenesis of atopic dermatitis is complex,and immune dysfunctions including type 2 inflammation,type 17 inflammation and keratinocyte reactions,epidermal barrier disruption and dysbiosis are closely related to the development of atopic dermatitis.So far,a variety of biologics targeting key molecules in the pathogenesis of atopic dermatitis have been developed.Some of them have been successfully applied in the clinical treatment and exhibited therapeutic efficacy and safety,providing a new direction for the treatment of atopic dermatitis.
作者 陈依慧 李捷 CHEN Yihui;LI Jie(Department of Dermatology,Xiangya Hospital,Central South University,National Clinical Research Center for Geriatric Fisorders,Xiangya Hospital,Central South Unirersity,Changsha 410008,China)
出处 《皮肤科学通报》 2023年第1期81-87,共7页 Dermatology Bulletin
基金 国家自然科学基金(82173424,81974476)
关键词 特应性皮炎 生物制剂 发病机制 2型炎症 Atopic dermatitis Biologics Pathogenesis Type 2 inflammation
  • 相关文献

同被引文献16

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部